



Please type a plus sign inside this box +

PTO/SB/08B(05/03)

Approved for use through 05/31/2003, OMB 0651-0031

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

---

Sheet

2 8f 2

|                        |                    |
|------------------------|--------------------|
| Application Number     | 10/663,109         |
| Filing Date            | September 15, 2003 |
| First Named Inventor   | Rustum, et al.     |
| Group Art Unit         | 1614               |
| Examiner Name          | Frederick F. Krass |
| Attorney Docket Number | 003551.00136       |

## NON PATENT LITERATURE DOCUMENTS

| Examiner Initials* | Cite No. <sup>1</sup> | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.                                      | T <sup>2</sup> |
|--------------------|-----------------------|--|----------------|
|                    | 8                     | KONOREV, et. al., <i>Cell-Permeable Superoxide Dismutase and Glutathione Peroxidase Mimetics Afford Superior Protection Against Doxorubicin-Induced Cardiotoxicity: The Role of Reactive Oxygen and Nitrogen Intermediates</i> , Archives Biochem. Biophysics, 1999, 368 (2), pp. 421-428, abstract. |                |
|                    | 9                     | KORAC, et al., <i>Doxorubicin, Toxicity to the Skin: Possibility of Protection With Antioxidants Enriched Yeast</i> , J. Dermat. Sci., 2001, 25 (1) pp. 45-52, abstract.   |                |
|                    | 10                    | CHEN, et al., <i>Protective Effects of Selenium Supplementation in Minimizing 5-Fluorouracil Induced Lipid Peroxidative Damage of the Small Intestine</i> , J. Trace Elements in Experimental Med., 1997, 10 (3), p. 163-171.  |                |
|                    | 11                    | VADGAMA J. et. al., <i>Effect of Selenium in Combination With Adriamycin or Taxol on Several Different Cancer Cells</i> , Anticancer Research 20:1391-1414, 2000.  |                |
|                    |                       |  |                |
|                    |                       |  |                |
|                    |                       |  |                |
|                    |                       |  |                |
|                    |                       |  |                |
|                    |                       |  |                |
| Examiner Signature |                       | Date Considered  |                |

**\*EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English Translation is attached.

**Burden Hour Statement:** The form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. Send to the Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450.